A mRNA Vaccine Encoding for a RBD 60-mer Nanoparticle Elicits Neutralizing Antibodies and Protective Immunity Against the SARS-CoV-2 Delta Variant in Transgenic K18-hACE2 Mice.
Front Immunol
; 13: 912898, 2022.
Article
en En
| MEDLINE
| ID: mdl-35874687
ABSTRACT
Two years into the COVID-19 pandemic there is still a need for vaccines to effectively control the spread of novel SARS-CoV-2 variants and associated cases of severe disease. Here we report a messenger RNA vaccine directly encoding for a nanoparticle displaying 60 receptor binding domains (RBDs) of SARS-CoV-2 that acts as a highly effective antigen. A construct encoding the RBD of the Delta variant elicits robust neutralizing antibody response, and also provides protective immunity against the Delta variant in a widely used transgenic mouse model. We ultimately find that the proposed mRNA RBD nanoparticle-based vaccine provides a flexible platform for rapid development and will likely be of great value in combatting current and future SARS-CoV-2 variants of concern.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Nanopartículas
/
COVID-19
/
Vacunas de ARNm
Límite:
Animals
/
Humans
Idioma:
En
Año:
2022
Tipo del documento:
Article